Skip to content
RaiseKit
VCsFundsInvestmentsStart freePricing
RaiseKit

The most comprehensive database of web3 VCs. Built and maintained by AI agents.

Directory

  • VCs
  • Funds
  • Investments
  • Writing
  • Funding
  • Sectors
  • Geography

Resources

  • RSS Feed
  • Changelog
  • Search
  • Compare VCs
  • Reports
  • Activity
  • Deploying

Subscribe

Weekly digest of VC insights and funding rounds.

Subscribe to digest →

© 2026 RaiseKit. Data updated nightly by AI agents.

PrivacyTermsSupportDelete accountRSS
  1. Sectors
  2. /Medical Devices

Medical Devices

100 VCs and 14 funds investing in Medical Devices

VCs investing in Medical Devices

Alex Morgan

Partner

88%

Khosla Ventures

Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.

Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.

IncubationPre-SeedSeed

Arielle Rothman

Investor

87%

BoxGroup

Check: No reliable Arielle-specific check size is public. BoxGroup describes itself as an earliest-stage investor, but founders should confirm current round fit and allocation directly rather than relying on third-party range estimates.

Arielle invests within BoxGroup's broad earliest-stage mandate. Her differentiated documented context is technical and translational: Harvard bioengineering research, founding a postpartum medical-device project, product work in fertility AI and neuromodulation, mechanical engineering at a bioelectronic-medicine startup, and consulting at BCG. This supports a credible ability to evaluate user need, clinical workflow, product design, manufacturing, regulatory planning and commercialization in technical health businesses. It does not establish an exclusive healthcare mandate or a personally published investment thesis.

Pre-seedSeedEarliest-stage company formation

Aristos Doxiadis

Partner Emeritus

85%

Big Pi Ventures

Check: No current personal check range: Aristos is Partner Emeritus and an official 2025 biography says he is not involved with Big Pi's later funds. Big Pi's current platform range is €0.5M–€30M across funds, but should not be attributed to him.

Aristos' historical investment lens combines strong technology, team, and market position with realistic commercialization targets. He favors research-based ventures that can bridge academia and industry, secure early adopters beyond a small home market, and use seed or Series A capital to build enough traction for international follow-on funding. His long private-equity career also brings attention to governance, business fundamentals, and social or economic impact.

SeedSeries AEarly Stage

Reinhard Krickl

Venture Partner

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Reinhard Krickl invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Nora Kaarela

Venture Partner

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Nora Kaarela invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Florian Eckhardt

Senior Advisor

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Florian Eckhardt is listed in a Senior Advisor capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

SeedSeries AEarly Stage

Lene Gerlach

Venture Partner

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Lene Gerlach invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Lene Dragesund

Senior Office Manager

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Lene Dragesund is listed in a Senior Office Manager capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

SeedSeries AEarly Stage

Pål R. Jensen

Senior Advisor Operations

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Pål R. Jensen is listed in a Senior Advisor Operations capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

SeedSeries AEarly Stage

Silje C. L. Ervik

Head of Legal

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Silje C. L. Ervik is listed in a Head of Legal capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

SeedSeries AEarly Stage

Vilde Fredheim

Director, Investor Relations & Business Development

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Vilde Fredheim is listed in a Director, Investor Relations & Business Development capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

SeedSeries AEarly Stage

Paal August Nordhagen

Director of Finance & Controlling

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Paal August Nordhagen is listed in a Director of Finance & Controlling capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

SeedSeries AEarly Stage

Camilla Olsen

Impact & ESG Manager

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Camilla Olsen is listed in a Impact & ESG Manager capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

SeedSeries AEarly Stage

Markèta Chlubnovà

Investment Analyst

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Markèta Chlubnovà invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Yun Yang

Investment Associate

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Yun Yang invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Markus Dietrich

Senior Investment Associate

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Markus Dietrich invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Miao He

Senior Investment Associate

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Miao He invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Georgina Askeland

Principal

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Georgina Askeland invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Roger Franklin

Partner

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Roger Franklin invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Walter Stockinger

Managing Partner

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Walter Stockinger invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Ingrid Teigland Akay

Managing Partner

80%

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Ingrid Teigland Akay invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

SeedSeries AEarly Stage

Zosia van Eesteren

Senior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Zosia van Eesteren invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Wim Schimmel

Operational Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wim Schimmel is listed in a Operational Partner capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Wessel van 't Klooster

Analyst - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wessel van 't Klooster invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Varsha Ram Balapa

Climate Specialist - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Varsha Ram Balapa is listed in a Climate Specialist - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Tristan Maguet

Senior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tristan Maguet invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Tom Klein Robbenhaar

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tom Klein Robbenhaar invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Susana Amorim

Investment Director - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Susana Amorim invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Stephanie Mooij

Head of Responsible Investment - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephanie Mooij is listed in a Head of Responsible Investment - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Stephan Wachtveitl

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephan Wachtveitl invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Stefan Luzi

Partner Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stefan Luzi invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Stacey Vrijhof

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stacey Vrijhof is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Sonia Hallen

Investment Manager Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Sonia Hallen invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Silke Kranz

Investment Manager - Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Silke Kranz invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Senay Sarsik

Office Manager Frankfurt - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Senay Sarsik is listed in a Office Manager Frankfurt - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Romy Wiering

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Romy Wiering is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Robert Stein

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Robert Stein invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Rik Maerten

Junior Fund Controller - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rik Maerten is listed in a Junior Fund Controller - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Redmar Koene

Investment Director - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Redmar Koene invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Raphael Arndt

Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Raphael Arndt invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Rafael Natanek

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rafael Natanek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Pommeline Korstanje

Associate Public Investments - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pommeline Korstanje invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Pieter van der Meer

Managing Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pieter van der Meer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Pheline Mulitze

Analyst - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pheline Mulitze invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Paulien Schippers

Finance Manager - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Paulien Schippers is listed in a Finance Manager - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Oksana van Vliet

Legal & AML/KYC counsel - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Oksana van Vliet is listed in a Legal & AML/KYC counsel - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Nellie Johnson

Executive Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Nellie Johnson is listed in a Executive Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Michel Verhoog

General Partner Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Michel Verhoog invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Max Steeman

Associate - Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Max Steeman invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Martin von Berg

Investment Director - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Martin von Berg invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Marloes Herbrink

Finance Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marloes Herbrink is listed in a Finance Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Marion Pouillard

Senior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marion Pouillard invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Luna van den Brink

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Luna van den Brink is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Ludo Suykerbuyk

General Counsel & Compliance Officer - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Ludo Suykerbuyk is listed in a General Counsel & Compliance Officer - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Lara Hilgert

Senior Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Lara Hilgert invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Katharina Mono

ESG & Impact Analyst - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Katharina Mono is listed in a ESG & Impact Analyst - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Kate Ebbenhorst

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kate Ebbenhorst is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Kasia Lorek

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kasia Lorek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Karthik Bolisetty

Investment Manager Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Karthik Bolisetty invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Josephine Bogaerts

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Josephine Bogaerts invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Joep Muijrers

General Partner Public Investments - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Muijrers invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Joep Heldens

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Heldens invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Jelte Goettsch

Senior Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jelte Goettsch invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Jasper van Gorp

Managing Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jasper van Gorp invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Janke Dittmer

General Partner Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Janke Dittmer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Jan Willem Bakker

Head of Investor Relations / Partner - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jan Willem Bakker is listed in a Head of Investor Relations / Partner - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Iskander Shadid

Junior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Iskander Shadid invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Hugo de Bruin

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Hugo de Bruin invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Henry Zubaida

Investment Director Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Henry Zubaida invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Hein Ploegmakers

General Partner Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Hein Ploegmakers invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Giel Modderman

Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Giel Modderman invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Geoff Pardo

General Partner Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Geoff Pardo invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Edwin de Graaf

Managing Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Edwin de Graaf invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Edward Hanlon

Investment Director - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Edward Hanlon invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Dirkjan Beugelsdijk

CFO - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Dirkjan Beugelsdijk is listed in a CFO - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Christiaan Sap

Operational Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Christiaan Sap is listed in a Operational Partner capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Chris Allen

Senior Associate HealthTech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Chris Allen invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Camille Sinkora

Analyst - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Camille Sinkora invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Boyd Rutten

Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Boyd Rutten invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Besmire Ahmati

Senior Associate Investor Relations & Fundraising - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Besmire Ahmati is listed in a Senior Associate Investor Relations & Fundraising - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Arthur Franken

General Partner Healthtech/Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Arthur Franken invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Ariane de Marcillac

Associate HealthTech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Ariane de Marcillac invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Nina Rijnders

Investor Relations

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Nina Rijnders is listed in a Investor Relations capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Pieter Wijffels

Venture Partner, New Markets

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Pieter Wijffels invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Niels van Kasteel

Corporate Account Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Niels van Kasteel is listed in a Corporate Account Manager capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Kathrin Ballesteros, PhD

Venture Partner, Therapeutics

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Kathrin Ballesteros, PhD invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Lydia Kalafateli, PhD

Venture Development Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Lydia Kalafateli, PhD is listed in a Venture Development Manager capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Henk Westendorp

Venture Partner, Cardiovascular & IGT

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Henk Westendorp invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Gina Melchner

Venture Partner, Lead General Healthtech

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Gina Melchner invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Taco van der Feltz, MD

Venture Partner

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Taco van der Feltz, MD invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Annabel van der Horst

Venture Developer

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Annabel van der Horst is listed in a Venture Developer capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Ellis Aune

Venture Development Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ellis Aune is listed in a Venture Development Manager capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Annameta Gericke

Venture Developer

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Annameta Gericke is listed in a Venture Developer capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Marta Scali, PhD

Sr. Venture Development Associate

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Marta Scali, PhD is listed in a Sr. Venture Development Associate capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Gabor Heltovics

Advisor

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Gabor Heltovics is listed in a Advisor capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Ljudmila Katchan, PhD

Entrepreneur in Residence

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ljudmila Katchan, PhD is listed in a Entrepreneur in Residence capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Rita Mendes, PhD

Venture Developer Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Rita Mendes, PhD is listed in a Venture Developer Manager capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Lars Olthof

Head of Venture Finance, Venture Investment Director

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Lars Olthof is listed in a Head of Venture Finance, Venture Investment Director capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Jaap Haemers

Investment Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Jaap Haemers invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Kevin Ranner

Investment Associate

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Kevin Ranner invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Funds focused on Medical Devices

Gilde Healthcare

Utrecht, Netherlands

61 people0 investments

NLC Health Ventures

Amsterdam, Netherlands

37 people0 investments

Wellington Partners

Munich, Germany

23 people0 investments

Kurma Partners

Paris, France / Munich, Germany

22 people0 investments

Hadean Ventures

Oslo, Norway and Stockholm, Sweden

18 people0 investments

RC Capital

Cincinnati, Ohio / Raleigh, North Carolina

18 people0 investments

Newton Biocapital

Brussels, Belgium and Tokyo, Japan

15 people0 investments

Panakès Partners

Milan, Italy

14 people0 investments

Boomerang Ventures

Indianapolis, Indiana

12 people0 investments

Clarevia

Madison, Wisconsin

12 people0 investments

S3 Ventures

Austin, Texas

11 people0 investments

i&i Bio

Prague, Czechia

8 people0 investments

Vesalius Biocapital

Luxembourg

5 people0 investments

Mutual Capital Partners

Westlake, Ohio

4 people0 investments